Acute Pancreatitis Market Is Projected To Grow By 2034 Owing To The Development Of Novel Therapies Delveinsight

(MENAFN- GetNews) The market dynamics for Acute Pancreatitis are expected to evolve during the forecast period, driven by the growing burden of acute pancreatic inflammation, increasing demand for effective disease management, and the need for therapies that address severe and recurrent episodes.

(Albany, New York) – October 28, 2026 – The market dynamics for Acute Pancreatitis are expected to evolve during the forecast period, driven by the growing burden of acute pancreatic inflammation, increasing demand for effective disease management, and the need for therapies that address severe and recurrent episodes. Additionally, the development of emerging therapies such as investigational calcium release-activated calcium (CRAC) channel inhibitors and other novel therapeutic approaches is expected to create new opportunities in the treatment landscape.

DelveInsight, a leading market research firm, provides an in-depth understanding of Acute Pancreatitis through its market research and epidemiology reports, covering historical and forecasted epidemiology, treatment patterns, emerging therapies, and market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Acute Pancreatitis Market

• The Acute Pancreatitis market is shaped by the burden of acute disease episodes, recurrent attacks, and the need for effective management of severe complications.

• DelveInsight's earlier market analysis estimated that the Acute Pancreatitis market across the seven major markets (7MM) was approximately USD 549.7 million in 2017, with the forecast extending to 2028 in that report.

• According to DelveInsight, the total number of diagnosed incident cases of Acute Pancreatitis across the 7MM was approximately 378,835 in 2017.

• The leading markets covered include the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

• Companies involved in the development of investigational treatments include those exploring CRAC channel inhibition and other approaches to reduce pancreatic inflammation and associated complications.

Keen to know more about the market? Visit

Key Factors Driving the Acute Pancreatitis Market

Increasing Disease Burden and Hospital Admissions: Acute Pancreatitis is a sudden inflammatory condition of the pancreas that can range from a mild, self-limiting episode to a severe disease associated with organ failure. Increasing recognition of disease complications and recurrent episodes contributes to the need for effective diagnosis, hospitalization, and treatment.

Unmet Need for Targeted Treatments: Current management primarily involves fluid resuscitation, pain control, nutritional support, and treatment of the underlying cause. Severe cases may require intensive care and management of complications. The limited availability of disease-modifying therapies highlights the need for novel treatments that can reduce inflammation and improve clinical outcomes.

Advances in Investigational Therapeutic Approaches: Research into calcium signaling, inflammatory pathways, and pancreatic acinar cell injury is creating opportunities for the development of novel treatments. Investigational therapies targeting these mechanisms may help address the limitations of supportive care, although their efficacy and safety require confirmation through clinical trials.

Acute Pancreatitis Competitive Landscape

The Acute Pancreatitis pipeline includes investigational candidates targeting inflammatory mechanisms and cellular pathways involved in pancreatic injury. One previously investigated candidate is CM4620 (Auxora), a CRAC channel inhibitor developed to regulate calcium signaling and potentially reduce inflammation associated with acute pancreatitis.

CM4620 has been evaluated as an investigational treatment for acute pancreatitis, including severe cases associated with systemic inflammatory responses. Its development reflects interest in therapies that target underlying disease mechanisms rather than focusing solely on symptom management. The current development and regulatory status of individual candidates should be verified before describing them as active pipeline therapies.

Discover more about emerging therapies @ Acute Pancreatitis Pipeline Insigh

Recent Developments in the Acute Pancreatitis Market

• 2019: DelveInsight's Acute Pancreatitis market report assessed the epidemiology, treatment landscape, and market outlook across the 7MM, with forecasts extending through 2028.

• Ongoing research: Clinical research continues to explore potential treatments that target inflammation and cellular injury associated with acute pancreatitis.

What is Acute Pancreatitis?

Acute Pancreatitis is a sudden inflammation of the pancreas that develops when digestive enzymes become activated prematurely and damage pancreatic tissue. Common causes include gallstones and excessive alcohol consumption, while other contributing factors include elevated triglyceride levels, certain medications, and medical procedures. Symptoms typically include severe upper abdominal pain, nausea, and vomiting. Severe cases can lead to systemic inflammation, organ failure, and life-threatening complications. Treatment focuses on supportive care, pain management, appropriate fluid therapy, nutritional support, and addressing the underlying cause.

Acute Pancreatitis Epidemiology Segmentation

The Acute Pancreatitis epidemiology section provides insights into the historical and forecasted patient pool across the leading markets. DelveInsight's epidemiology report covers the study period 2021–2034, segmented into:

• Total Diagnosed Incident Cases of Acute Pancreatitis

• Etiology-specific Diagnosed Incident Cases of Acute Pancreatitis

• Severity-specific Diagnosed Incident Cases of Acute Pancreatitis

• Gender-specific Diagnosed Incident Cases of Acute Pancreatitis

• Diagnosed Incident Cases of Recurrent Acute Pancreatitis

Scope of the Acute Pancreatitis Market Report

• Therapeutic Assessment: Current treatment practices and emerging therapies for Acute Pancreatitis.

• Market Dynamics: Historical market trends, forecast assumptions, treatment opportunities, and unmet medical needs.

• Key Companies: Companies involved in the development of investigational therapies targeting acute pancreatic inflammation.

• Key Therapy: CM4620 (Auxora), previously investigated as a CRAC channel inhibitor.

• Competitive Intelligence Analysis: Pipeline product profiles, clinical development assessment, and therapeutic landscape evaluation.

• Unmet Needs: The need for effective disease-modifying treatments, improved management of severe episodes, and approaches to reduce complications and recurrence.

To know more about the Acute Pancreatitis pipeline, visit @ Acute Pancreatitis Clinical Trials and Therapeutic Assessmen

Table of Contents

Acute Pancreatitis Market Report Introduction

Executive Summary for Acute Pancreatitis

Acute Pancreatitis Market Overview

Acute Pancreatitis Background and Overview

Acute Pancreatitis Epidemiology and Patient Population

Country-Specific Patient Population of Acute Pancreatitis

Acute Pancreatitis Current Treatment and Medical Practices

Acute Pancreatitis Unmet Needs

Acute Pancreatitis Emerging Therapies

Acute Pancreatitis Market Outlook

Country-Wise Acute Pancreatitis Market Analysis

Acute Pancreatitis Drug Uptake and Market Share

Acute Pancreatitis Market Drivers

Acute Pancreatitis Market Barriers

Acute Pancreatitis Competitive Landscape

Acute Pancreatitis Report Methodology

DelveInsight Capabilities

Disclaimer

About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

MENAFN28102026003238003268ID1111881712